Abstract 171P
Background
Atezo+Bev is recognized as the standard of care for systemic treatment-naïve uHCC pts. The key to prolonging survival is to manage vascular endothelial growth factor inhibitor-related adverse events while considering continued treatment. Proteinuria is the main adverse event leading to Bev interruption. However, the relationship between Bev-related proteinuria and renal dysfunction is unclear. Therefore, we retrospectively investigated the impact of proteinuria after starting Atezo+Bev on renal function in uHCC pts.
Methods
We performed a single-arm retrospective study of 100 uHCC pts treated with Atezo+Bev between Sep 25, 2020 and May 31, 2022, at Kindai University, Japan. The impact of proteinuria on renal function during Atezo+Bev treatment was analyzed in terms of the correlation between changes in urine protein creatinine ratio (UPCR) and estimated glomerular filtration rate (eGFR) relative to baseline.
Results
We analyzed 100 pts with data at baseline and at least twice after starting Atezo+Bev. The median age was 74 years (range 41‒89) and 75% were male. Performance status was 0–1 in 99% and 2 in 1%. Barcelona Clinic Liver Cancer stage was B in 62% and C in 38%. Child–Pugh class was A5, A6, in 61%, 29%. 60% had hypertension and 37% had diabetes mellitus. During the Atezo+Bev treatment period, the median (interquartile range) maximum increase from baseline in UPCR was 0.39 (0.08 to 2.05) and the median maximum decline from baseline in eGFR was −7.5 (−20.5 to −3.0) mL/min/1.73 m2. The Pearson and Spearman correlation coefficients (95% confidence interval) between the maximum UPCR increase and the maximum eGFR decline were −0.13 (−0.32 to 0.07) and −0.13 (−0.32 to 0.07), respectively.
Conclusions
The change in UPCR was not correlated with the change in eGFR during Atezo+Bev treatment. For safety concerns, Bev interruption criteria are set according to the degree of proteinuria, but we found that proteinuria does not necessarily impair renal function. Physicians should consider the risk-benefit profile when deciding whether to skip Bev in pts who develop proteinuria during treatment.
Clinical trial identification
UMIN000050692.
Editorial acknowledgement
Medical writing support was provided by Nicholas D. Smith (EMC K.K.), and funded by Chugai Pharmaceutical Co., Ltd.
Legal entity responsible for the study
Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine.
Funding
Chugai Pharmaceutical Co., Ltd.
Disclosure
K. Ueshima: Financial Interests, Personal, Invited Speaker, Concurrent roles with an advisory board: Chugai, Eisai, Takeda, Lilly Japan; Financial Interests, Personal, Invited Speaker: AstraZeneca, Otsuka, Taiho, Sumitomo, MSD, Kowa, EA pharma, AbbVie, Aska; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Local PI: Chugai. M. Kudo: Financial Interests, Personal, Invited Speaker: Eisai, Chugai, Eli Liiy, Bayer, Takeda, AstraZeneca; Financial Interests, Institutional, Research Grant: Otsuka, EA Pharma, Taiho, Eisai, AbbVie, GE Healthcare, Chugai. All other authors have declared no conflicts of interest.
Resources from the same session
540P - Phase III study of serplulimab plus chemotherapy as first-line therapy for advanced squamous non-small cell lung cancer: ASTRUM-004 Asian subgroup
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
541P - Integrated analysis of randomized controlled trials IMpower130 and IMpower132 for advanced non-squamous non-small cell lung cancer (NSCLC)
Presenter: Hibiki Udagawa
Session: Poster Display
Resources:
Abstract
542P - First-line HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy in advanced/recurrent squamous non-small cell lung cancer: A phase II study
Presenter: Zhen Wang
Session: Poster Display
Resources:
Abstract
543P - A multicenter retrospective study to investigate risk factors for immune checkpoint inhibitor-induced pneumonitis in non-small cell lung cancer patients with comorbid interstitial pneumonia
Presenter: Yuriko Ishida
Session: Poster Display
Resources:
Abstract
544P - Single cell level investigation of blood cells representing immune checkpoint inhibitor response in lung adenocarcinoma patients
Presenter: Juyong Seong
Session: Poster Display
Resources:
Abstract
545P - Completion of pembrolizumab in advanced non-small cell lung cancer: Real-world outcomes after two years of therapy (COPILOT)
Presenter: Andrew Fantoni
Session: Poster Display
Resources:
Abstract
546P - Combination therapy with anti-PD-1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation
Presenter: Akio Tada
Session: Poster Display
Resources:
Abstract
547P - Immunotherapy outcome in advanced/metastatic lung cancer patients in real-world experience: Indian data
Presenter: Naveen K
Session: Poster Display
Resources:
Abstract
548P - B-Myb acts as a mentor instant promoter in non-small cell lung cancer by modifying the PD-1/PD-L1 axis
Presenter: Pan Xu
Session: Poster Display
Resources:
Abstract
549P - Drug-induced interstitial lung disease in patients with non-small cell lung cancer treated with immunotherapy for postoperative recurrence: Evaluation of CT findings and histopathological findings of the background lung
Presenter: shodai fujimoto
Session: Poster Display
Resources:
Abstract